Patents versus patients? Antiretroviral therapy in India

New England Journal of Medicine

Volumn 353, Issue 8, 2005, Pages 749-751

  Havlir, Diane V ^a,b   Hammer, Scott M ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; STAVUDINE; ANTIRETROVIRUS AGENT; GENERIC DRUG;

DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LAW; LIPOATROPHY; LIVER TOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SHORT SURVEY; TERATOGENICITY; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMICS; HEALTH CARE AND PUBLIC HEALTH; INTERNATIONAL COOPERATION; LEGAL APPROACH; LEGAL ASPECT; PATENT; UNITED STATES;

HEALTH CARE AND PUBLIC HEALTH; LEGAL APPROACH;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; HIV INFECTIONS; HUMANS; INDIA; INTERNATIONAL COOPERATION; PATENTS; UNITED STATES;

EID: 23944453415     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058106     Document Type: Short Survey

References (0)